[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2606546T3 - Compuesto destinado a la absorción bucal de nicotina con el objetivo de dejar de fumar - Google Patents

Compuesto destinado a la absorción bucal de nicotina con el objetivo de dejar de fumar Download PDF

Info

Publication number
ES2606546T3
ES2606546T3 ES10721627.7T ES10721627T ES2606546T3 ES 2606546 T3 ES2606546 T3 ES 2606546T3 ES 10721627 T ES10721627 T ES 10721627T ES 2606546 T3 ES2606546 T3 ES 2606546T3
Authority
ES
Spain
Prior art keywords
weight
concentration
nicotine
group
flavanones
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10721627.7T
Other languages
English (en)
Inventor
Dobromil KOSÍK
Milan Dittrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heglund AS
Original Assignee
Heglund AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CZ20090080A external-priority patent/CZ200980A3/cs
Application filed by Heglund AS filed Critical Heglund AS
Application granted granted Critical
Publication of ES2606546T3 publication Critical patent/ES2606546T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465Nicotine; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/45Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484Glycyrrhiza (licorice)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/61Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/82Theaceae (Tea family), e.g. camellia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/87Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/906Zingiberaceae (Ginger family)
    • A61K36/9066Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/18Antioxidants, e.g. antiradicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

El compuesto destinado a la aplicación bucal de nicotina al sistema circulatorio y a la distribución al sistema nervioso central, aplicable en forma coloidal o en forma de un dispositivo atomizador con el fin de dejar de fumar o de su sustitución en el caso de ser las condiciones para fumar desfavorables. De conformidad con la invención en referencia, el compuesto se destaca por el hecho, de que contiene una solución de nicotina en forma de base y/o de sus sales con un ácido orgánico en una concentración de 0,10 a 4,00% del peso, la concentración más apropiada es de 0,20 a 1,00% del peso. Además contiene materias que tienen efecto mucolítico del grupo de acetilcisteina en una concentración de 3,00 a 30,0% del peso y/o fitocomplejos que poseen efecto mucolítico, adquiridos mediante la extracción de las plantas seleccionadas del grupo Primula veris, Primula elatior, Hedera helix, Eucalyptus globulus nebo Liquiritia glabra en una concentración de0,50 a 15,00% del peso de fitocomplejo con un efecto antioxidante seleccionado del grupo de flavonas, flavonoles, flavanones flavanonoles, isoflavonas, neoflavonoides, antocianidinas, pro-antociadinas y de sus oligómeros y polímeros, adquiridos mediante la extracción de las plantas Camellia sinensis, Curcuma longa, Rosmarinus officinalis, Sylibium marianum, Vitis vinifera, Ginkgo biloba, Euterpe oleracea, Vaccinium myrtillus, Morinda citrifolia, Malpighia glabra, las cuales contienen además un retardador (amortiguador) que modifica la acidez a un rango de pH de 7,0 a 9,0.

Description

imagen1
imagen2
imagen3
imagen4
Ejemplos de realización:
Ejemplos 1, 2 y 3:
Componente:
Composición (% del peso)
Muestra nro.. 1
Muestra nro. 2 Muestra nro. 3
Nicotina
1,00 2,00 3,00
Ácido cítrico
0,95 1,55 2,10
Acetilcisteina
25,00 15,00 5,00
Ascorbil fosfato de sodio
3,00 5,00
Sorbato de potasio
0,10 0,10 0,10
Benzoato de sodio
0,10 0,10 0,10
Sucralosa
0,07 0,08 0,10
Glicerina
5,00 10,00 15,00
Grape seeda extrakt
1,50 0,75
Perfume
0,10 0,20 0,35
Aceite de ricina hidrogenado pegilado
0,12 0,12 0,12
Hidróxido de sodio
q.s. pH 7,0 - 9,0 q.s. pH 7,0 - 9,0 q.s. pH 7,0 - 9,0
Agua
do 100,00g do 100,00g do 100,00g
Procedimiento de preparación: en el agua se disuelven componentes que se agregan individualmente de manera
5 paulatina. La solución se filtra según sea necesario y se vierte en recipientes de presión, dotados de una válvula dosificadora o en recipientes cerrados provistos de una válvula dosificadora, impulsada por una bomba de accionamiento manual.
Aprovechamiento industrial
De conformidad con la invención, el compuesto puede ser fabricado por la industria farmacéutica. El preparado 10 resulta apropiado para la absorción transmucosa de nicotina con el objetivo de dejar de fumar.
6

Claims (1)

  1. imagen1
ES10721627.7T 2009-02-11 2010-02-03 Compuesto destinado a la absorción bucal de nicotina con el objetivo de dejar de fumar Active ES2606546T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CZ20090080 2009-02-11
CZ20090080A CZ200980A3 (cs) 2009-02-11 2009-02-11 Kompozice urcená k bukální absorpci nikotinu za úcelem odvykání kourení
CZ20090829 2009-12-09
CZ2009829 2009-12-09
PCT/CZ2010/000011 WO2010091649A2 (en) 2009-02-11 2010-02-03 A composition for buccal absorption of nicotine for the purpose of smoking cessation

Publications (1)

Publication Number Publication Date
ES2606546T3 true ES2606546T3 (es) 2017-03-24

Family

ID=69162740

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10721627.7T Active ES2606546T3 (es) 2009-02-11 2010-02-03 Compuesto destinado a la absorción bucal de nicotina con el objetivo de dejar de fumar

Country Status (14)

Country Link
US (2) US20110293535A1 (es)
EP (1) EP2395974B1 (es)
JP (1) JP2012517402A (es)
KR (1) KR20110114552A (es)
CN (1) CN102316850A (es)
AU (1) AU2010213244A1 (es)
CA (1) CA2751271A1 (es)
EA (1) EA201100896A1 (es)
ES (1) ES2606546T3 (es)
IL (1) IL212720A (es)
PT (1) PT2395974T (es)
SG (1) SG171870A1 (es)
WO (1) WO2010091649A2 (es)
ZA (1) ZA201103096B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10244793B2 (en) 2005-07-19 2019-04-02 Juul Labs, Inc. Devices for vaporization of a substance
US20140166027A1 (en) * 2012-12-14 2014-06-19 Richard C. Fuisz Enhanced Delivery of Nicotine, THC, Tobacco, Cannabidiol or Base Alkaloid from an Electronic Cigarette or Other Vapor Producing Device Through Use of an Absorption Conditioning Unit
US20140166028A1 (en) * 2012-12-14 2014-06-19 Richard C. Fuisz Enhanced Delivery of Nicotine, THC, Tobacco, Cannabidiol or Base Alkaloid from an Electronic Cigarette or Other Vapor or Smoke Producing Device Through Use of an Absorption Conditioning Unit
US10638792B2 (en) 2013-03-15 2020-05-05 Juul Labs, Inc. Securely attaching cartridges for vaporizer devices
IL297399B2 (en) * 2013-05-06 2024-02-01 Juul Labs Inc Nicotine salt formulations for aerosol devices and methods thereof
CA2913489C (en) * 2013-06-07 2019-04-30 Remi Shrivastava Composition for topical application comprising glycerol and tannins
US10463069B2 (en) * 2013-12-05 2019-11-05 Juul Labs, Inc. Nicotine liquid formulations for aerosol devices and methods thereof
US10076139B2 (en) 2013-12-23 2018-09-18 Juul Labs, Inc. Vaporizer apparatus
US20160366947A1 (en) 2013-12-23 2016-12-22 James Monsees Vaporizer apparatus
CN110664012A (zh) 2013-12-23 2020-01-10 尤尔实验室有限公司 蒸发装置系统和方法
US10159282B2 (en) 2013-12-23 2018-12-25 Juul Labs, Inc. Cartridge for use with a vaporizer device
US10058129B2 (en) 2013-12-23 2018-08-28 Juul Labs, Inc. Vaporization device systems and methods
USD842536S1 (en) 2016-07-28 2019-03-05 Juul Labs, Inc. Vaporizer cartridge
USD825102S1 (en) 2016-07-28 2018-08-07 Juul Labs, Inc. Vaporizer device with cartridge
CN107427067B (zh) 2014-12-05 2020-10-23 尤尔实验室有限公司 校正剂量控制
CN104770864B (zh) * 2015-02-13 2016-08-24 华健 一种清热润喉的电子雾化液及其制备方法
WO2016133890A1 (en) * 2015-02-19 2016-08-25 Srq Patent Holdings, Llc Compositions for e-cigarettes
GB201516729D0 (en) * 2015-09-22 2015-11-04 The Technology Partnership Plc Liquid nicotine formulation
CA2914089C (en) 2015-12-03 2018-12-18 Euro-Pharm International Canada Inc. Nicotine-containing liquid formulations and uses thereof
US10405582B2 (en) 2016-03-10 2019-09-10 Pax Labs, Inc. Vaporization device with lip sensing
USD849996S1 (en) 2016-06-16 2019-05-28 Pax Labs, Inc. Vaporizer cartridge
USD851830S1 (en) 2016-06-23 2019-06-18 Pax Labs, Inc. Combined vaporizer tamp and pick tool
USD836541S1 (en) 2016-06-23 2018-12-25 Pax Labs, Inc. Charging device
USD887632S1 (en) 2017-09-14 2020-06-16 Pax Labs, Inc. Vaporizer cartridge
KR20210119488A (ko) * 2019-01-25 2021-10-05 차이나 토바코 후난 인더스트리얼 코포레이션 리미티드 수계 전자 담배 액체
CN111000283A (zh) * 2019-12-13 2020-04-14 武汉红金叶新材料科技有限公司 一种用于气溶胶装置的电子烟油及其制备方法和应用
SE546142C2 (en) * 2020-04-03 2024-06-11 Liw Innovation Ab New compositions for oral use
JP2024519516A (ja) * 2021-04-23 2024-05-15 トーマス メネギニ 消毒剤及びその使用
CN116649576B (zh) * 2023-06-14 2024-10-29 深圳市吉迩科技有限公司 一种含有抑菌抗氧化组合物的尼古丁口含制品及其制备方法
CN117099995A (zh) * 2023-09-05 2023-11-24 东莞市吉纯生物技术有限公司 一种抗氧化电子雾化液及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63196524A (ja) * 1987-02-10 1988-08-15 Wakunaga Pharmaceut Co Ltd 経粘膜吸収型制ガン作用調節剤
IT1265312B1 (it) * 1993-12-21 1996-10-31 Indena Spa Formulazioni contenenti carotenoidi e procarotenoidi associati a polifenoli nella prevenzione dei danni da abnorme produzione di
PT910339E (pt) * 1996-04-12 2005-05-31 Novadel Pharma Inc Aerossol polar bucal
US20080138399A1 (en) * 1999-07-16 2008-06-12 Aradigm Corporation Dual release nicotine formulations, and systems and methods for their use
US6277855B1 (en) * 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US20040002520A1 (en) * 2002-07-01 2004-01-01 Soderlund Patrick L. Composition and method for cessation of Nicotine cravings
US7244709B2 (en) * 2004-05-10 2007-07-17 Nastech Pharamecutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
EP2526943B1 (en) * 2006-02-13 2017-03-22 Orient Pharma (Samoa) Co, Ltd Liquid formulation comprising an alpha-2 receptor agonist (e.g. clonidin) and oxybutynin (anti-muscarinic agent) for the treatment of sialorrhoea
WO2008069970A2 (en) * 2006-12-01 2008-06-12 Aradigm Corporation Nicotine formulations, kits and systems and methods for their use
US20080286340A1 (en) * 2007-05-16 2008-11-20 Sven-Borje Andersson Buffered nicotine containing products
GB0712308D0 (en) * 2007-06-25 2007-08-01 Kind Group Ltd An inhalable composition

Also Published As

Publication number Publication date
JP2012517402A (ja) 2012-08-02
EP2395974A2 (en) 2011-12-21
CA2751271A1 (en) 2010-08-19
WO2010091649A4 (en) 2010-12-29
KR20110114552A (ko) 2011-10-19
SG171870A1 (en) 2011-07-28
IL212720A (en) 2016-02-29
WO2010091649A3 (en) 2010-11-11
AU2010213244A1 (en) 2010-08-19
WO2010091649A2 (en) 2010-08-19
PT2395974T (pt) 2016-12-14
EP2395974B1 (en) 2016-09-07
IL212720A0 (en) 2011-07-31
US20200022905A1 (en) 2020-01-23
ZA201103096B (en) 2011-12-28
CN102316850A (zh) 2012-01-11
EA201100896A1 (ru) 2012-01-30
US20110293535A1 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
ES2606546T3 (es) Compuesto destinado a la absorción bucal de nicotina con el objetivo de dejar de fumar
Zhu et al. Prophylactic effects of quercetin and hyperoside in a calcium oxalate stone forming rat model
AR113749A1 (es) Formulaciones cannabinoides sintéticas y a base de plantas de inicio rápido y acción prolongada
BRPI0710485B1 (pt) composições líquidas úteis no tratamento de doenças respiratórias
AR078812A1 (es) Preparacion que comprende aminoacidos y plantas y su actividad en la detoxificacion del alcohol
ES2488407T3 (es) Preparación farmacéutica que contiene lipasa de origen bacteriano
RU2011138101A (ru) Фармацевтическая композиция, проявляющая противовоспалительные свойства
US11446232B2 (en) Natural skin penetrating moisturizer formulations
ES2720954T3 (es) Formulaciones estabilizadas de estatina
CL2009000309A1 (es) Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2.
CY1111369T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει 3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολη και παρακεταμολη
ES2606141T3 (es) Composiciones para el tratamiento de úlceras periféricas de diversos orígenes
WO2022162711A1 (en) Composition for the treatment of painful and/or inflammatory states
CL2014000035A1 (es) Composicion en forma de un gel para la preparacion de un producto alimenticio, que comprende agua en una cantidad de 30 a 70% en peso, saborizantes desde 1 a 40%, sal desde 10 a 25% y agentes gelificantes desde 0,15 a 12% que contienen al menos agar y xantano; y proceso para preparar dicha composicion.
HRP20140215T1 (hr) Kombinacija koja sadrži paklitaksel za lijeäśenje raka jajnika
Alibasyah et al. potensi antibakteri ekstrak jahe (Zingiber officinale Roscoe) terhadap Porphyromonas gingivalis secara in vitro
ES2624593T3 (es) Sal de hidrobromuro de un compuesto anti-VIH.
BRPI1014412A8 (pt) Nanocápsulas de poliarginina
CL2007000485A1 (es) Sal de alisquereno; procedimiento de preparacion; composicion farmaceutica que comprende a dicha sal; y uso del compuesto para el tratamiento de enfermedades que puedan ser moduladas mediante la inhibicion de la renina.
Gupta et al. Comparison of antimicrobial activities of clove oil and its extract on some food borne microbes
UY32600A (es) Formulación en lípidos de un promotor de la apoptosis
CN103585660A (zh) 一种新型空气清新剂
BR112014030288A2 (pt) composição farmacêutica
RU2013137782A (ru) Водный ионный раствор, содержащий морскую воду, по меньшей мере одно соединение, изначально не смешивающееся с морской водой
FR2938766B1 (fr) Composition cosmetique et/ou pharmaceutique comprenant un hydrolysat de feuille de vigne (vitis vinifera l.) en tant que principe actif activateur de l'aconitase et protecteur des mitochondries